Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lilly Misses 3Q Forecasts as Sales Slip on Key Drugs

By AP | October 25, 2016

INDIANAPOLIS (AP) — Eli Lilly’s profit slipped 3 percent in the third quarter and the drugmaker fell well short of Wall Street expectations as competition and a loss of patent protection chopped revenue for some key products.

Company shares started sliding early Tuesday after Lilly also reaffirmed its forecast for 2016 earnings and gave its revenue guidance a slight increase. The company expects adjusted earnings of between $3.50 and $3.60 per share on revenue ranging from $20.8 billion to $21.2 billion.

Analysts expect earnings of $3.59 per share on $21.21 billion in revenue, according to FactSet.

Sales of Lilly’s top seller, the insulin Humalog, and the cancer treatment Alimta both tumbled 9 percent to $640.8 million and $570.4 million respectively. Meanwhile another key seller, the erectile dysfunction drug Cialis, rose only 4 percent to $588.2 million.

Lilly said competition in the United States led to decreased demand for Alimta, which also faced the loss of patent exclusivity in several countries. Lower prices that included changes in rebate and discount estimates helped drop Humalog sales 14 percent in the U.S.

Higher research and development costs and lower investment gains also mixed into the company’s lower-than-expected performance.

Overall, Eli Lilly and Co. earned $778 million in the third quarter. Adjusted results came in at 88 cents per share.

Analysts expected, on average, earnings of 96 cents per share, according to Zacks Investment Research.

Revenue climbed 5 percent to $5.19 billion but still fell short of forecasts.

Four analysts surveyed by Zacks expected $5.35 billion.

Shares of the Indianapolis-based drugmaker fell 1.5 percent, or $1.17, to $76.40 in premarket trading.

Lilly shares had fallen almost 8 percent since the beginning of the year, while the Standard & Poor’s 500 index has climbed slightly more than 5 percent.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE